Atrial fibrillation and congestive heart failure: Specific considerations at the intersection of two common and important cardiac disease sets

Journal of Cardiovascular Electrophysiology

Volumn 13, Issue 4, 2002, Pages 399-405

  Ehrlich, Joachim R ^a   Nattel, Stanley ^b   Hohnloser, Stefan H ^a  

^a GOETHE UNIVERSITY   (Germany)

^b MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Atrial fibrillation; Congestive heart failure; Epidemiology; Pathophysiology; Treatment

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; DOFETILIDE; SOTALOL;

CATHETER ABLATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEFIBRILLATOR; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ELECTROPHYSIOLOGY; HEART ATRIUM FIBRILLATION; HEART PACING; HEMODYNAMICS; HUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TORSADE DES POINTES; TREATMENT PLANNING;

EID: 0036109440     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1540-8167.2002.00399.x     Document Type: Review

References (84)

1. Has the survival of the heart failure population changed? Lessons from trials
2. Epidemiologic features of chronic atrial fibrillation: The Framingham study
3. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT studies
4. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation. Observation from the Veterans Affairs Congestive Heart Failure Trial on Antiarrhythmic Therapy (CHF-STAT)
5. Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients
6. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
7. Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham heart study
8. Predictors of primary atrial fibrillation and concomittant clinical and hemodynamical changes in patients with chronic heart failure: A prospective study in 344 patients with baseline sinus rhythm
9. Functional capacity before and after cardioversion of atrial fibrillation: A controlled study
10. Proarrhythmia with class III antiarrhythmic drugs: Definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications
11. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
12. The effect of digoxin on mortality and morbidity in patients with heart failure
13. Management of atrial fibrillation in the setting of heart failure
14. Prognostic significance of atrial fibrillation in patients at a tertiary medical center referred for heart transplantation because of severe heart failure
15. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular dysfunction: A retrospective analysis of the SOLVD trials
16. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: A Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) substudy
17. Comparison of one-year mortality in women versus men with chronic congestive heart failure
18. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation
19. Promotion of atrial fibrillation by heart failure in dogs: Atrial remodeling of a different kind
20. Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation
21. Effects of experimental heart failure on atrial cellular and ionic electrophysiology
22. Arrhythmogenesis and contractile dysfunction in heart failure: Roles of sodium-calcium exchange, inward rectifier potassium current, and residual beta-adrenergic responsiveness
23. Tarantula peptide inhibits atrial fibrillation
24. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure
25. Signal transduction underlying arrhythmogenic atrial remodeling due to congestive heart failure
26. Ionic mechanism of action potential prolongation in ventricular myocytes from dogs with pacing-induced heart failure
27. + channel in human cardiac myocytes. Alterations in channel behavior in myocytes isolated from patients with idiopathic dilated cardiomyopathy
28. Pacing-induced heart failure causes a reduction of delayed rectifier potassium currents along with decreases in calcium and transient outward currents in rabbit ventricle
29. Arrhythmogenic ionic remodeling: Adaptive responses with maladaptive consequences
30. Ionic remodeling of cardiac Purkinje cells by congestive heart failure
31. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial
32. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized trials
33. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation
34. Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: Analysis of the cardiac arrhythmia suppression trial
35. Comparative hemodynamic effects of procainamide, tocainide, and encainide in severe chronic heart failure
36. Antiarrhythmic drug classifications: A critical appraisal of their history, present status, and clinical relevance
37. Randomized trial of low-dose amiodarone in severe congestive heart failure
38. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia
39. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure
40. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: A meta-analysis of individual data from 6500 patients in randomized trials
41. Amiodarone to prevent recurrence of atrial fibrillation
42. Prevention of implantable-defibrillator shocks by treatment with sotalol
43. Sex difference in risk of torsade de pointes with d,l-sotalol
44. Contrasting efficacy of dofetilide in differing experimental models of atrial fibrillation
45. Clinical and electrophysiological effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectoris
46. Dofetilide in patients with congestive heart failure and left ventricular dysfunction
47. QTc interval as a guide to select those patients with congestive heart failure and reduced left ventricular systolic function who will benefit from antiarrhythmic treatment with dofetilide
48. Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital
49. Repolarization abnormalities, arrhythmia and sudden death in canine tachycardia-induced cardiomyopathy
50. Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia
51. Early outcome of initiating amiodarone for atrial fibrillation in advanced heart failure
52. Amiodarone and torsades de pointes in patients with advanced heart failure
53. Tachycardia-induced cardiomyopathy: A review of animal models and clinical studies
54. Tachycardiomyopathy in patients with supraventricular tachycardia with emphasis on atrial fibrillation
55. Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomized trial
56. Effectiveness and cost of digoxin treatment for atrial fibrillation and flutter
57. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: A crossover open-label study of five drug regimens
58. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure
59. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial
60. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction
61. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter
62. Clinical outcome after ablation and pacing therapy for atrial fibrillation. A meta-analysis
63. Spontaneous initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins
64. Circumferential radiofrequency ablation of pulmonary vein ostia. A new anatomic approach for curing atrial fibrillation
65. Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci
66. The surgical treatment of atrial fibrillation
67. Right and left atrial radiofrequency catheter therapy of paroxysmal atrial fibrillation
68. Modification of the substrate for maintenance of idiopathic human atrial fibrillation: Efficacy of radiofrequency ablation using nonfluoroscopic catheter guidance
69. Atrioverter: An implantable device for the treatment of atrial fibrillation
70. Initial clinical experience with ambulatory use of an implantable atrial defibrillator for conversion of atrial fibrillation
71. Spontaneous episodes of atrial fibrillation after implantation of the Metrix Atrioverter: Observations on treated and nontreated episodes
72. Implantation of an arrhythmia management system for ventricular and supraventricular tachyarrhythmias
73. New devices and hybrid therapy for treatment of atrial fibrillation
74. Multisite or alternate site pacing for the prevention of atrial fibrillation
75. Effects of different atrial pacing modes on atrial electrophysiology. Implicating the mechanism of biatrial pacing in prevention of atrial fibrillation
76. Evaluation of biatrial pacing, right atrial pacing, and no pacing in patients with drug refractory atrial fibrillation
77. Prevention of recurrent atrial fibrillation with chronic dual-site right atrial pacing
78. Long-term outcome of patients with drug-refractory atrial flutter and fibrillation after single- and dual-site right atrial pacing for arrhythmia prevention
79. Biatrial synchronous pacing for atrial arrhythmia prevention: The SYNBIAPACE study
80. Impact of cardiac resynchronization therapy using hemodynamically optimized pacing on left ventricular remodeling in patients with congestive heart failure and ventricular conduction disturbances
81. Tissue Doppler echocardiographic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure
82. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure
83. Incidence, predictive factors, and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure